These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

275 related articles for article (PubMed ID: 2171556)

  • 1. Production of Marek's disease vaccine.
    Ben-Nathan D; Lustig S
    Adv Biotechnol Processes; 1990; 14():347-65. PubMed ID: 2171556
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and safety of cell associated vaccines against Marek's disease virus grown in a continuous cell line from chickens.
    Geerligs H; Quanz S; Suurland B; Spijkers IE; Rodenberg J; Davelaar FG; Jongsma B; Kumar M
    Vaccine; 2008 Oct; 26(44):5595-600. PubMed ID: 18706949
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Embryo vaccination against Marek's disease with serotypes 1, 2 and 3 vaccines administered singly or in combination.
    Sharma JM; Witter RL
    Avian Dis; 1983; 27(2):453-63. PubMed ID: 6307248
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Development of a cell line system susceptible to infection with vaccine strains of MDV.
    Abujoub AA; Williams DL; Reilly JD
    Acta Virol; 1999; 43(2-3):186-91. PubMed ID: 10696443
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Protection and synergism by recombinant fowl pox vaccines expressing genes from Marek's disease virus.
    Nazerian K; Witter RL; Lee LF; Yanagida N
    Avian Dis; 1996; 40(2):368-76. PubMed ID: 8790888
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Early posthatch protection against Marek's disease in chickens vaccinated in ovo with a CVI988 serotype 1 vaccine.
    Zhang Y; Sharma JM
    Avian Dis; 2001; 45(3):639-45. PubMed ID: 11569737
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Marek's disease--the disease and its prevention by vaccination.
    Biggs PM
    Br J Cancer Suppl; 1975 Mar; 2():152-5. PubMed ID: 170953
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Derivation, safety and efficacy of a Marek's disease vaccine developed from an Australian isolate of very virulent Marek's disease virus.
    Karpathy RC; Firth GA; Tannock GA
    Aust Vet J; 2002; 80(1-2):61-6. PubMed ID: 12180882
    [TBL] [Abstract][Full Text] [Related]  

  • 9. New serotype 2 and attenuated serotype 1 Marek's disease vaccine viruses: comparative efficacy.
    Witter RL
    Avian Dis; 1987; 31(4):752-65. PubMed ID: 2831867
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Protection of chickens against very virulent infectious bursal disease virus (IBDV) and Marek's disease virus (MDV) with a recombinant MDV expressing IBDV VP2.
    Tsukamoto K; Kojima C; Komori Y; Tanimura N; Mase M; Yamaguchi S
    Virology; 1999 May; 257(2):352-62. PubMed ID: 10329546
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Protective efficacy of Marek's disease virus (MDV) CVI-988 CEF65 clone C against challenge infection with three very virulent MDV strains.
    de Boer GF; Groenendal JE; Boerrigter HM; Kok GL; Pol JM
    Avian Dis; 1986; 30(2):276-83. PubMed ID: 3015113
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Marek's disease in turkeys: lack of protection by vaccination.
    Elmubarak AK; Sharma JM; Witter RL; Sanger VL
    Am J Vet Res; 1982 Apr; 43(4):740-2. PubMed ID: 6280536
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of a bivalent vaccine against Marek's disease.
    Pruthi AK; Gupta RK; Sadana JR
    Res Vet Sci; 1987 Mar; 42(2):145-9. PubMed ID: 3035660
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of a combination vaccine containing MDV CVI 988 strain and HVT against challenge with very virulent MDV.
    Geerligs HJ; Weststrate MW; Pertile TL; Rodenberg J; Kumar M; Chu S
    Acta Virol; 1999; 43(2-3):198-200. PubMed ID: 10696445
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Vaccinal control of Marek's disease: current challenges, and future strategies to maximize protection.
    Baigent SJ; Smith LP; Nair VK; Currie RJ
    Vet Immunol Immunopathol; 2006 Jul; 112(1-2):78-86. PubMed ID: 16682084
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Influence of maternal antibody on efficacy of embryo vaccination with cell-associated and cell-free Marek's disease vaccine.
    Sharma JM; Graham CK
    Avian Dis; 1982; 26(4):860-70. PubMed ID: 6297450
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Influence of B-haplotype on the relative efficacy of Marek's disease vaccines of different serotypes.
    Bacon LD; Witter RL
    Avian Dis; 1993; 37(1):53-9. PubMed ID: 8383961
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Partial inhibition by turkey herpesvirus of serotype 2 Marek's disease virus plaque formation and in vivo infectivity.
    Witter RL; Bacon LD; Calvert JG
    Avian Dis; 1994; 38(4):800-9. PubMed ID: 7702514
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Difference between influences of homologous and heterologous maternal antibodies on response to serotype-2 and serotype-3 Marek's disease vaccines.
    King D; Page D; Schat KA; Calnek BW
    Avian Dis; 1981; 25(1):74-81. PubMed ID: 6268052
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prevention of Marek's disease: a review.
    Purchase HG
    Cancer Res; 1976 Feb; 36(2 pt 2):696-700. PubMed ID: 766959
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.